LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced that it has licensed a new sulfoalkyl ether-alkyl ether cyclodextrin derivative from the University of Kansas. CyDex’s core strategy is to license its Captisol to established pharmaceutical companies that are interested in using the patented technology to improve product candidates in their pipelines. Five FDA-approved, Captisol-enabled® medications are now being marketed by three CyDex licensees: Pfizer, Bristol-Myers Squibb and Prism Pharmaceuticals.
